Luspatercept with thalidomide for beta-thalassemia patients
Part of Blood & lymphatic clinical trials.
This study tests whether a combination of two drugs, luspatercept and thalidomide, can help people with beta-thalassemia who need regular blood transfusions. It aims to reduce the number of transfusions needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have beta-thalassemia and need regular blood transfusions (6 to 30 units in the past 6 months, with no more than 42 days between transfusions).
- You are generally healthy and active (ECOG score 0 or 1).
- You have not used thalidomide, erythropoietin, or hydroxyurea in the past 6 months.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for beta thalassemia. A modified virus is used to deliver a working gene to your blood stem cells, which may help your body produce normal hemoglobin and reduce the need for blood transfusions.
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This study looks at how well a medication called Luspatercept works for adults with transfusion-dependent beta-thalassemia, a blood condition that requires regular blood transfusions. Researchers want to understand how it helps people in the Middle East.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
Hear when a new Transfusion-dependent β-thalassemia Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.